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Abstract
Background: Previous meta-analysis suggested that transdermal fentanyl was not inferior to sustained-release oral 
morphine in treating moderate-severe cancer pain with less adverse effects. Now, we updated the data and performed 
a systematic review.
Methods: Updated cohort studies on transdermal fentanyl and oral morphine in the treatment of cancer pain were 
searched in electronic databases including CBMdisc, CNKI, VIP, Medline, EMBASE and Cochrane Library. Primary end 
points assessed by meta-analysis were remission rate of pain and incidence of adverse effects. Quality of life was 
assessed by systematic review, which was the second end point.
Results: 32 cohort studies, which included 2651 patients, were included in present study. The remission rate in 
transdermal fentanyl group and sustained-release oral morphine group were 86.60% and 88.31% respectively, there 
was no significant difference [RR = 1.13, 95% CI (0.92, 1.38), P = 0.23]. Compared with oral morphine group, there were 
less adverse effects in terms of constipation [RR = 0.35, 95% CI (0.27, 0.45), P < 0.00001], nausea/vomiting [RR = 0.57, 
95% CI (0.49, 0.67), P < 0.00001], and vertigo/somnolence [RR = 0.59, 95% CI (0.51, 0.68), P < 0.00001] in transdermal 
fentanyl group. Six of selected trials supported either transdermal fentanyl or sustained-release oral morphine 
improved QOL of cancer patients and one of them showed more patients got better QOL after sustained-release oral 
morphine transferred to transdermal fentanyl.
Conclusions: Our study showed again that both transdermal fentanyl and oral morphine had the same efficacy in the 
treatment of moderate-severe cancer pain in Chinese population, but the former might have less adverse effects and 
better quality of life.
Background
For patients with cancer, up to 70% suffered from pain
caused by their disease or its treatment [1]. For patients
with advanced cancer, pain was described as moderate-
severe in approximately 40%-50% and as very severe in
25%-30% [2]. Because pain was an important symptom
and occurred frequently in cancer patients, especially for
moderate-severe cancer pain, relief of pain should there-
fore be seen as part of a comprehensive pattern of cancer
care.
Since the 1980s, treatment of cancer pain was based on
the WHO analgesic ladder. Strong opioids were classified
at the highest step of the analgesic ladder. But studies of
cancer pain control consistently revealed that up to half
of patients received inadequate analgesia and 30% did not
receive appropriate drugs for their pain [1]. In China, sus-
tained-release oral morphine and transdermal fentanyl
were strong opioids available for the treatment of moder-
ate-severe cancer pain.
Fentanyl is a lipid soluble synthetic opioid, which can
be delivered in a transdermal controlled systemic delivery
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formulation for up to 72 hours. Transdermal fentanyl was
accepted to be an effective drug for treating moderate-
severe cancer pain. Because it takes 12-24 hours for
serum levels to stabilize after starting the patch or chang-
ing the dose, it was less flexible and suitable for patients
with unstable pain. However, transdermal fentanyl may
reduce the rates of some typical opioid-related adverse
effects, particularly constipation [3]. In addition, trans-
dermal fentanyl was conveniently administrated, which
simplified the procedure of chronic pain treatment and
improved the compliance for using the analgesic.
Three systematic reviews of European and American
literatures suggested both transdermal fentanyl and sus-
tained-release oral morphine could effectively control
moderate-severe cancer pain, but some adverse effects
(mainly constipation) seemed to favor transdermal opi-
ates in the preference of patients with moderate-severe
cancer pain [4-6]. Our previous meta-analysis of 12 Chi-
nese literatures also found similar result [7]. Since then,
many clinical trials were conducted again in China to
compare the two drugs [8-39]. Therefore, we updated the
data and re-performed a systematic review of all related
literatures to evaluate efficacy and adverse effects of
transdermal fentanyl and oral morphine treating moder-
ate-severe cancer pain in Chinese population.
Methods
Search Strategy
Two authors independently performed a systematic
review of electronic databases including Chinese Bio-
medical Literature Analysis and Retrieval System (CBM-
disc), China National Knowledge Infrastructure (CNKI),
Chongqi VIP Information (VIP), Medline, EMBASE and
Cochrane library. The following keywords were used in
the search: transdermal fentanyl, morphine, sustained-
release morphine, Durogesic, MS Contin, Morphine
Hydrochloride-Southwest Pharm. In addition to the
online search, references from original articles also were
scanned to capture missing clinical trial data that met our
inclusion criteria. All papers comparing transdermal fen-
tanyl with sustained-release oral morphine (MS Contin
or Morphine Hydrochloride-Southwest Pharm) were
examined. No language restrictions were applied. The
deadline of last search was December 31, 2009.
Inclusion Criteria
Study design
Trials should be prospective cohort study, which were
matched for sex, age, performance status, and type of
tumor.
Study population
Patients were Chinese and suffered from moderate-
severe cancer pain. In addition, patients who were eligible
for trials didn't receive radiotherapy, chemotherapy or
immunotherapy in 30 days prior to analgesics administra-
tion, and patients had no history of hypersensitive to opi-
oid or opioid abuse. Patients had adequate hematological,
renal, cardiac and hepatic function.
Interventions
The treatment arm received transdermal fentanyl (Duro-
gesic), the control arm received sustained-release oral
morphine (MS Contin or Morphine Hydrochloride-
Southwest Pharm). The treatment duration was 15 days
at least.
End Points
The primary end points were remission rate of pain and
incidence of opioids-related adverse effects. The second
end point was quality of life (QOL).
Data Extraction
Two primary reviewers (QY and DRX) assessed all
abstracts that were identified from the above-mentioned
sources. Both reviewers independently selected trials
according to inclusion criteria. Disagreements were
resolved by consensus or by the third reviewer (ZMJ).
F o l l o w i n g  d a t a  w e r e  r e q u e s t e d :  n u m b e r  o f  p a t i e n t s
recruited, number of patients had remission, number of
patients had non-remission, number of patients experi-
enced constipation, number of patients experienced nau-
sea and vomiting (nausea/vomiting), number of patients
experienced vertigo and somnolence (vertigo/somno-
lence) and QOL from each trial.
Assessment of Study Quality
We assessed all manuscripts that met the selection crite-
ria for quality. Quality assessment was based on pub-
lished checklists. The checklists were adapted from
MOOSE standard, which include six measures in total:
prospective study design, groups comparable on all
important confounding factors, outcome assessed blind
to exposure status, follow-up long enough for outcomes
to occur (defined as over 15 days), relation between out-
come and exposure appropriately measured, and appro-
priate statistical analyses used. The maximum quality
score was 6 point [40,41]. The quality scores were showed
in additional file 1.
Statistical Analysis
The primary end points variables were defined as dichot-
omous data (e.g., remission rate of pain used variables as
follows: the effective or the ineffective after treatment).
We standardized the therapeutic results by obtaining the
relative risk (RR). RR is defined as a ratio of risk of uncon-
trolled pain or adverse effects occurring in transdermal
fentanyl group versus sustained-release oral morphine
group. To test for heterogeneity among the trials,
Cochran's χ2 test was used. P-value of more than 0.05 for
the χ2-test indicated a lack of heterogeneity across theYang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:67
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studies, so pooled estimation of the RRs of each study
was calculated by the fixed effects model. Otherwise, the
random effects model was used. An estimate of the
potential publication bias was carried out by funnel plot,
in which the standard error (SE) of log RR of each study
was plotted against its log RR. An asymmetric plot sug-
gested a possible publication bias. All analyses were per-
f o r m e d  s t r i c t l y  w i t h  R e v M a n  s o f t w a r e  ( v e r s i o n  4 . 2 . 8 ,
Cochrane). P value less than 0.05 was considered as sig-
nificant in difference.
Results
Characteristics of selected trials
578 trials were examined in the preliminary review; 32 of
them were considered eligible and included in the analy-
sis. The data extracted from 32 trials were shown in addi-
tional file 1[8-39]. A total of 2651 cancer pain patients
were treated in all selected trials, 1296 with transdermal
fentanyl, and 1355 with sustained-release oral morphine.
30 of selected trials were included in the analysis of clini-
cal efficacy; and 31, 31 and 28 of selected trials were
included in the analysis of constipation, nausea/vomiting
and vertigo/somnolence. Only 6 trials supplied data
about QOL evaluated in different criteria [9,14,17,32-34].
Sustained-release oral morphine was Morphine Hydro-
chloride-Southwest Pharm in 8 of selected trials
[8,16,19,25,27,29,32,33]. Trials were excluded from the
analysis for one or more of the following reasons: uncor-
related, review, case report, no valid data, no followed-up
time, and non-cancer pain. Trials applied either numeri-
cal rating scale or visual analogue scales for assessing
cancer pain. The criterion of remission of cancer pain
was described as follow. Five categories of pain relief: cat-
egory 0, no remission (pain didn't release); category 1,
mild remission (pain released one quarter); category 2,
moderate remission (pain released a half); category 3,
obvious remission (pain released three quarters); cate-
gory 4, complete remission (pain disappeared). Pain can
be controlled denotes that patients gain category 2 or
above of pain relief. Pain can't be controlled denotes
patients gain category 1 or below of pain relief. Toxicity
profiles were reported according to the WHO's criteria.
QOL was reported in different criteria, which based on
different QOL scale.
Remission Rate of Pain
2491 patients from 30 cohort studies, 1216 in the trans-
dermal fentanyl group and 1275 in the sustained-release
oral morphine group were included in the meta-analysis
of clinical efficacy. Overall effect of remission rate of pain
was analyzed by a fixed-effect model (fixed), because test
for heterogeneity among the trials was not significant (p
= 1.00). The remission rate in transdermal fentanyl group
and sustained-release oral morphine group were 86.60%
and 88.31% respectively, there was no significant differ-
ence [RR = 1.13, 95% CI (0.92, 1.38), P = 0.23]. More
details were shown in Table 1 and the forest plot was
shown in additional file 2.
Adverse Effects
Data on main adverse effects was summarized in the
additional file 1. Overall effect of constipation and nau-
sea/vomiting were analyzed by a random-effect model
(random), because test for heterogeneity among the trials
was significant (p < 0.05). Compared with sustained-
release oral morphine, pooled RR of constipation was
0.35 [95%CI (0.27, 0.45), p < 0.00001]; pooled RR of nau-
sea/vomiting was 0.57 [95%CI (0.49, 0.67), p < 0.00001].
Overall effect of vertigo/somnolence was analyzed by a
fixed-effect model (fixed), because test for heterogeneity
among the trials was not significant (p = 0.08). Pooled RR
of vertigo/somnolence was 0.59 [95%CI (0.51, 0.68), p <
0.00001] in patients used transdermal fentanyl. In short,
transdermal fentanyl caused less adverse effects in com-
parison of sustained-release oral morphine in patients
with moderate-severe cancer pain. More details were
showed in Table 1 and the forest plots were shown in
additional file 2.
Quality of Life
Six of selected trials were included to systematic review
of QOL [9,14,17,32-34]. Primary endpoints of QOL were
appetite, sleep, activity of daily living, mental states, emo-
Table 1: Comparisons between Transdermal Fentanyl and Sustained-release Oral Morphine
Endpoints No. of patients/studies RR (95% CI)a Pb Ph
c
Remission rate 2491/30 1.13 (0.92, 1.38) 0.23 1.00
Constipation 2593/31 0.35 (0.27, 0.45) < 0.00001 < 0.00001
Nausea/vomiting 2593/31 0.57 (0.49, 0.67) < 0.00001 0.009
Vertigo/somnolence 2300/28 0.59 (0.51, 0.68) < 0.00001 0.08
a RR, relative risk; 95% CI, 95% confidence interval
b p value of significance tests of RR = 1
c p value of heterogeneity testsYang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:67
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tion, communication and interest. QOL was not pooled
for meta-analysis because different QOL evaluation crite-
ria were used. After review of these six trials, all the data
from each trial supported either transdermal fentanyl or
sustained-release oral morphine improved QOL of can-
cer patients. In trial of Pang et al., more patients got bet-
ter QOL after sustained-release oral morphine
transferred to transdermal fentanyl [34].
Publication Bias Assessment
In the funnel plot, the selected trials were plotted by the
RR of the endpoints for meta-analysis and SE (logRR) as
abscissa and ordinate. Small sample studies scattered
widely at the bottom of the graph, while the spread nar-
rowed for larger sample studies. Funnel plot was symmet-
rically distributed, and there was no influence of
publication bias in our study (Figure 1).
Sensitivity Analysis
Sensitivity analysis should be used to analyze stability of
data when heterogeneity existed among selected trials. A
single study involved in the present meta-analysis was
deleted each time to reflect the influence of the individual
data-set to the pooled RRs of constipation and nausea/
vomiting, and the corresponding pooled RRs were not
materially altered (data not shown).
Discussion
Opioids were main drugs for managing pain according to
WHO analgesic ladder. Oral morphine is generally
accepted to be the drug of choice for maintenance ther-
apy of moderate-severe cancer pain. But transdermal fen-
tanyl is challenging the position because of its
convenience, relative lower incidence of constipation and
higher compliance of patients reported in clinical trials
[42-44]. Clark et al and Tassinari et al in three meta-anal-
yses reported two drugs were equally effective in improv-
ing the score of pain with less adverse effects for
transdermal fentanyl [4-6].
In our meta-analysis, transdermal fentanyl and oral
morphine were effective in controlling moderate-severe
cancer pain. 86.60% patients with cancer pain would
experience 50% or greater pain reduction by transdermal
fentanyl, in contrast, 88.31% for oral morphine, but it
didn't reach significant difference [RR = 1.13, 95% CI
(0.92, 1.38), P = 0.23]. The result supported NCCN guide-
line (adult cancer pain-V.1.2009) that transdermal fenta-
nyl and oral morphine were alterative drugs for
maintenance therapy of stable moderate-severe cancer
pain. In other words, both drugs were also effective in
treating moderate-severe cancer pain in Chinese popula-
Figure 1 Funnel plot of test for publication bias. The vertical line represents the meta-analysis summary estimate, and the scatter represents single 
study. In the absence of publication bias, studies will be distributed symmetrically right and left the vertical line. logRR, natural logarithm of the RR; 
SE(logRR), standard error of the logRR.Yang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:67
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tion, which might suggest both of opioids have no race
choose.
Adverse effect and QOL might be more important indi-
cations for choosing drug when the therapeutic effect was
similar between two drugs. In our meta-analysis, trans-
dermal fentanyl caused less adverse effect compared with
oral morphine, which the risk reduced 65% in constipa-
tion, 43% in nausea/vomiting and 41% in vertigo/somno-
lence. All reached significant difference (P  < 0.05).
Constipation caused by opioids was irreversible and even
severely influenced QOL, but other adverse effects were
reversible after 1-2 weeks use of opioids. Therefore, con-
stipation is a common reason for patients refusing to con-
tinue to use opioid analgesics. Because of the less adverse
effects, especially for constipation, transdermal fentanyl
might be easier to improve QOL. In present study, 6 trials
reported data on QOL and showed either transdermal
fentanyl or sustained-release oral morphine improved
QOL of cancer patients [9,14,17,32-34]. Especially, one of
trials supported more patients got better QOL after sus-
tained-release oral morphine transferred to transdermal
fentanyl [34].
Cost effectiveness was not an endpoint in the present
systematic review, but it was a valuable index to evaluate
a drug for clinical use. 2 out of selected trials reported
data about cost effectiveness that transdermal fentanyl
had higher expenditure to control certain pain than oral
morphine [35,36]. However, we should keep in mind that
cost effectiveness was affected by many factors in fact and
only 2 out of 32 trials reported data about cost effective-
ness when we concluded cost effectiveness was higher in
transdermal fentanyl.
Similar with European and American data [4-6], our
data also showed that both transdermal fentanyl and sus-
tained-release oral morphine were effective in treating
stable moderate-severe cancer pain in Chinese popula-
tion with less adverse effects for transdermal fentanyl.
However, two differences should be pointed out. First,
QOL was only analyzed in our study, and data suggested
that transdermal fentanyl potentially improved QOL of
cancer pain patients and resulted in better compliance
compared with oral morphine. Second, more patients
were included in the present systematic review and all
patients were Chinese.
To explain the results reasonably, several issues should
b e  c o n s i d e r e d  a s  f o l l o w .  F i r s t ,  t h e  d a t a  s o u r c e  w a s
extracted from abstracted data and not individual patient
data (IPD). In general, an IPD-based meta-analysis would
give a more robust estimation for the association; there-
fore, we should interpret the results with care, especially
for a positive result. Clearly, further investigations using
IPD should be conducted to examine the main end
points. Second, all selected trials were cohort studies,
which is not most suitable clinical trial to explore the dif-
ference of two drugs. Third, heterogeneity existed among
the trials when pooled analysis of adverse effects (consti-
pation and nausea/vomiting), fortunately, the data was
not materially changed in sensitivity analysis. Fourth, side
effects seemed to be lower in our selected trials com-
pared with clinical practice. We thought that these results
might be explained in two aspects of small sample in sin-
gle trial and better tolerance in Chinese population. At
last, transdermal fentanyl takes 12-24 hours for serum
levels to stabilize after starting the patch and dose incre-
ment was trouble in clinic practice, so it is less flexible
and needs to be used with caution in patients with unsta-
ble pain.
Conclusions
In summary, the present study supported that transder-
mal fentanyl and sustained-release oral morphine were
effective for maintenance therapy of moderate-severe
cancer pain in Chinese population, and the former might
have less adverse effects. Our results were similar with
European and American data, which might suggest that
both of opioids have no race choose. In addition, our data
suggested transdermal fentanyl might improve QOL
more easily. Well-designed randomised control trials
should be further conducted in this area.
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